atomoxetine hydrochloride has been researched along with modafinil in 20 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (35.00) | 29.6817 |
| 2010's | 10 (50.00) | 24.3611 |
| 2020's | 3 (15.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Holcomb, HH; Schweitzer, JB | 1 |
| Pliszka, SR | 1 |
| Waxmonsky, JG | 1 |
| Arnsten, AF; Biederman, J; Culpepper, L; Doyle, AE; Faraone, SV; Safren, SA; Spencer, TJ; Weiss, MD; Wilens, TE | 1 |
| Ivanov, I; Newcorn, JH | 1 |
| DeVane, CL; Donovan, JL; Gibson, BB; Jiang, Y; Markowitz, JS; Wang, JS; Zhu, HJ | 1 |
| Bukstein, OG; Crismon, ML; Manos, MJ; Tom-Revzon, C | 1 |
| Hu, TW; Lang, HC; Scheffler, RM | 1 |
| Amore, M; Ciccocioppo, R; Donnini, C; Gerra, G; Gerra, ML; Kalluppi, M; Malagoli, M; Raggi, MA; Saracino, MA; Somaini, L | 1 |
| Franke, AG; Huss, M; Konrad, A; Lieb, K | 1 |
| Howland, RH | 1 |
| Aagaard, L; Hansen, EH | 1 |
| Aagaard, L; Hansen, EH; Warrer, P | 1 |
| Agrawal, N; Dougall, D; Poole, N | 1 |
| Connemann, BJ; Gahr, M; Schönfeldt-Lecuona, C; Zeiss, R | 1 |
| Casavant, MJ; Chounthirath, T; Hodges, NL; King, SA; Smith, GA; Spiller, HA | 1 |
| Bai, Z; Charach, A; Chojecki, D; Eagles, C; Elliott, J; Hossain, A; Hsieh, SC; Husereau, D; Johnston, A; Kelly, SE; Mamdani, M; Skidmore, B; Tsakonas, E; Wells, GA | 1 |
| Böker, KO; Di Fazio, P; Jäckle, K; Lehmann, W; Schilling, AF; Wagener, N; Weiser, L | 1 |
| Juárez, J; Yepez, JE | 1 |
8 review(s) available for atomoxetine hydrochloride and modafinil
| Article | Year |
|---|---|
Drugs under investigation for attention-deficit hyperactivity disorder.
Topics: Animals; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Central Nervous System Stimulants; Clinical Trials as Topic; Cyclobutanes; Donepezil; Histamine Agonists; Humans; Indans; Modafinil; Nootropic Agents; Piperidines; Propylamines | 2002 |
Non-stimulant treatment of attention-deficit/hyperactivity disorder.
Topics: Adrenergic alpha-Agonists; Antidepressive Agents; Antidepressive Agents, Tricyclic; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Bupropion; Child; Clinical Trials as Topic; Humans; Modafinil; Practice Guidelines as Topic; Propylamines; Treatment Outcome | 2003 |
Nonstimulant therapies for attention-deficit hyperactivity disorder (ADHD) in children and adults.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Behavior Therapy; Benzhydryl Compounds; Bupropion; Child; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Modafinil; Propylamines; Psychotherapy; Psychotropic Drugs | 2005 |
Changes and challenges: managing ADHD in a fast-paced world.
Topics: Algorithms; Antihypertensive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Central Nervous System Stimulants; Child; Comorbidity; Drug Delivery Systems; Family; Guanfacine; Humans; Modafinil; Patient Compliance; Prodrugs; Propylamines; Quality of Life; Randomized Controlled Trials as Topic; Substance-Related Disorders; Treatment Outcome | 2007 |
Promising medications for cocaine dependence treatment.
Topics: Acetylcysteine; Atomoxetine Hydrochloride; Baclofen; Benzhydryl Compounds; Buprenorphine; Cocaine-Related Disorders; Fructose; Humans; Modafinil; Ondansetron; Patents as Topic; Propylamines; Topiramate | 2011 |
[Stimulant and non-stimulant medication in current and future therapy for ADHD].
Topics: Adrenergic alpha-2 Receptor Agonists; Adult; Amphetamines; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Central Nervous System Stimulants; Child; Dextroamphetamine; Fatty Acids, Omega-3; Guanfacine; Histamine Agonists; Humans; Isoxazoles; Lisdexamfetamine Dimesylate; Memantine; Methylphenidate; Modafinil; Off-Label Use; Propylamines; Pyridines; Pyrrolidines; Receptors, AMPA | 2012 |
Pharmacotherapy for chronic cognitive impairment in traumatic brain injury.
Topics: Adolescent; Adult; Aged; Atomoxetine Hydrochloride; Benzhydryl Compounds; Brain Injuries; Chronic Disease; Cognition; Cognition Disorders; Humans; Middle Aged; Modafinil; Nootropic Agents; Piperidines; Randomized Controlled Trials as Topic; Rivastigmine | 2015 |
Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
Topics: Adult; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Bayes Theorem; Bupropion; Central Nervous System Stimulants; Dextroamphetamine; Drug-Related Side Effects and Adverse Reactions; Female; Guanfacine; Humans; Lisdexamfetamine Dimesylate; Male; Methylphenidate; Modafinil; Network Meta-Analysis; Quality of Life; Randomized Controlled Trials as Topic | 2020 |
12 other study(ies) available for atomoxetine hydrochloride and modafinil
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
New developments in the treatment of ADHD.
Topics: Antidepressive Agents, Tricyclic; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Bupropion; Central Nervous System Stimulants; Child; Clonidine; Cognitive Behavioral Therapy; Guanfacine; Humans; Modafinil; Nicotinic Agonists; Physician's Role; Primary Health Care; Propylamines; Treatment Outcome | 2006 |
Psychopharmacologic treatment of attention-deficit/hyperactivity disorder and disruptive behavior disorders.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit and Disruptive Behavior Disorders; Benzhydryl Compounds; Central Nervous System Stimulants; Conduct Disorder; Humans; Modafinil; Neurobiology; Pediatrics; Propylamines; Psychopharmacology; Selective Serotonin Reuptake Inhibitors; United States | 2007 |
Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein.
Topics: Adenosine Triphosphate; Amphetamine; Animals; Atomoxetine Hydrochloride; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Biological Transport; Central Nervous System Stimulants; Cyclosporins; Dose-Response Relationship, Drug; Doxorubicin; Isomerism; LLC-PK1 Cells; Methylphenidate; Modafinil; Propylamines; Reproducibility of Results; Rhodamine 123; Swine; Transfection | 2008 |
The discrepancy in attention deficit hyperactivity disorder (ADHD) medications diffusion: 1994-2003--a global pharmaceutical data analysis.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Central Nervous System Stimulants; Drug Costs; Drug Industry; Economics; Healthcare Disparities; Humans; Methylphenidate; Modafinil; Propylamines; Time Factors; United States | 2010 |
The use of dopaminergic and stimulant drugs for the treatment of depression.
Topics: Amphetamines; Antidepressive Agents; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Benzhydryl Compounds; Brain; Central Nervous System Stimulants; Depressive Disorder, Major; Dextroamphetamine; Dopamine; Dopamine Agents; Drug Therapy, Combination; Epinephrine; Humans; Lisdexamfetamine Dimesylate; Methylphenidate; Modafinil; Norepinephrine; Propylamines | 2012 |
Adverse drug reaction labelling for atomoxetine, methylphenidate and modafinil: comparison of product information for oral formulations in Australia, Denmark and the United States.
Topics: Administration, Oral; Adverse Drug Reaction Reporting Systems; Atomoxetine Hydrochloride; Australia; Benzhydryl Compounds; Central Nervous System Stimulants; Denmark; Drug Industry; Drug Labeling; Humans; Methylphenidate; Modafinil; Propylamines; United States | 2013 |
Comparison of pregnancy and lactation labeling for attention-deficit hyperactivity disorder drugs marketed in Australia, the USA, Denmark, and the UK.
Topics: Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Australia; Benzhydryl Compounds; Central Nervous System Stimulants; Contraindications; Data Collection; Denmark; Drug Labeling; Female; Humans; Lactation; Methylphenidate; Modafinil; Pregnancy; Propylamines; United Kingdom; United States | 2014 |
Sensitivity of Quantitative Signal Detection in Regards to Pharmacological Neuroenhancement.
Topics: Adrenergic Uptake Inhibitors; Adverse Drug Reaction Reporting Systems; Atomoxetine Hydrochloride; Australia; Benzhydryl Compounds; Canada; Central Nervous System Stimulants; Drug-Related Side Effects and Adverse Reactions; Excitatory Amino Acid Antagonists; France; Germany; Humans; Italy; Memantine; Methylphenidate; Modafinil; Pharmacovigilance; Spain; Substance-Related Disorders; United Kingdom; United States; Wakefulness-Promoting Agents | 2017 |
Pediatric ADHD Medication Exposures Reported to US Poison Control Centers.
Topics: Adolescent; Age Distribution; Amphetamine; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; Child, Preschool; Drug Misuse; Humans; Infant; Infant, Newborn; Medication Errors; Methylphenidate; Modafinil; Patient Admission; Poison Control Centers; Retrospective Studies; Suicide, Attempted; United States; Young Adult | 2018 |
Psychostimulants Modafinil, Atomoxetine and Guanfacine Impair Bone Cell Differentiation and MSC Migration.
Topics: Adult; Atomoxetine Hydrochloride; Attention Deficit Disorder with Hyperactivity; Cell Differentiation; Central Nervous System Stimulants; Child; Guanfacine; Humans; Ligands; Methylphenidate; Modafinil; Nootropic Agents; Osteoprotegerin; Receptor Activator of Nuclear Factor-kappa B | 2022 |
Atomoxetine promotes incentive value of modafinil and sensitizes exploratory behavior.
Topics: Animals; Atomoxetine Hydrochloride; Dopamine; Exploratory Behavior; Male; Modafinil; Motivation; Rats; Rats, Wistar | 2023 |